Genmab — December 2015
-
i hvilken indiation?
-
det lyder aggressivt - er de eneste data vi har ikke fra det her fase 1/2 safety rr cll combo studie - http://www.bloodjournal.org/content/early/2015/06/30/blood-2014-12-617522?sso-checked=true
-
næh - det tror jeg såmænd heller ikke. Men jeg tænker, at det er eneste studie, der berettiger opstart af en fase III
-
This study is a Multicentre, Open-label, Phase II study of Daratumumab and Dexamethasone in MM patients. Eligible patients must have a symptomatic RRMM with a measurable disease, resistant or refractory to Bortezomib and Lenalidomide and Pomalidomide.
-
sikke en sur dag - C20cap dykker endda under 1.000
-
In vivo, ADCT-301 demonstrates dose-dependent antitumor activity against subcutaneous and disseminated lymphoma models. For example, in the Karpas 299 xenograft model, 10/10 tumor-free survivors are observed following a single dose of 0.5 mg/kg, whereas Adcetris
gives only a modest delay in mean tumor growth at 0.5 mg/kg, despite this tumor expressing three-fold higher target antigen levels for this drug.https://ash.confex.com/ash/2015/webprogram/Paper80592.html -
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind